Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2

Tumor Biology

Volumn 36, Issue 9, 2015, Pages 6691-6700

  Lu, Ruijing ^a,b   Ji, Ziliang ^c   Li, Xiaoqing ^a   Qin, Jie ^a   Cui, Guanghui ^a   Chen, Jing ^a   Zhai, Qingna ^a,b   Zhao, Chunjuan ^a   Zhang, Wei ^d   Yu, Zhendong ^a  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b Maternity and Child Health Care Hospital of Shenzhen   (China)

^c Longgang District People s Hospital   (China)

^d Biomedical Research Institute   (China)

Author keywords

miR 200a; Renal cell carcinoma; TGFB2; Tumor suppressor

Indexed keywords

MESSENGER RNA; MICRORNA 200A; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA2; MICRORNA; MIRN200 MICRORNA, HUMAN; TGFB2 PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL; RENAL CANCER CELL LINE; TGFB2 GENE; TUMOR INVASION; BIOSYNTHESIS; CELL MOTION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84947129992     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3355-9     Document Type: Article

References (43)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.
2. Campbell SC, Flanigan RC, Clark JI. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4(5):363–72.
3. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7(6):327–38.
4. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.
5. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401–14.
6. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.
7. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, et al. Genome‐wide microRNA expression profiling in renal cell carcinoma: significant down‐regulation of miR‐141 and miR‐200c. J Pathol. 2008;216(4):418–27.
8. White N, Khella H, Grigull J, Adzovic S, Youssef Y, Honey R, et al. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 2011;105(11):1741–9.
9. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3(1):44.
10. Zhou L, Chen J, Li Z, Li X, Hu X, Huang Y, et al. Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One. 2010;5(12):e15224.
11. Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther. 2010;10(3):219–22.
12. Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian X-W, et al. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun. 2010;391(1):535–41.
13. Feng J, Wang J, Chen M, Chen G, Wu Z, Ying L, et al. miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncol Rep. 2015;33(2):713–20.
14. Barron N, Keenan J, Gammell P, Martinez VG, Freeman A, Masters JR, et al. Biochemical relapse following radical prostatectomy and miR‐200a levels in prostate cancer. Prostate. 2012;72(11):1193–9.
15. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009;114(3):457–64.
16. Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, Fuse M, et al. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet. 2013;58(8):508–16.
17. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–64.
18. Lu R, Ji Z, Li X, Zhai Q, Zhao C, Jiang Z, et al. miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin. 2014;140(3):387–97.
19. Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo X, et al. Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun. 2012;419(4):621–6.
20. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol. 2008;5(3):115–9.
21. Park S-M, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22(7):894–907.
22. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008;283(22):14910–4.
23. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601.
24. Becker LE, Takwi AAL, Lu Z, Li Y. The role of miR-200a in mammalian epithelial cell transformation. Carcinogenesis. 2014;36(1):2–12.
25. Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/β-catenin signaling pathway. Mol Cell Biol. 2009;29(21):5923–40.
26. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem. 2011;286(29):25992–6002.
27. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420.
28. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213(2):374–83.
29. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–64.
30. Glasgow E, Mishra L. Transforming growth factor-β signaling and ubiquitinators in cancer. Endocr Relat Cancer. 2008;15(1):59–72.
31. Hill JJ, Tremblay T-L, Cantin C, O'Connor-McCourt M, Kelly JF, Lenferink A. Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transition. Proteome Sci. 2009;7(2):1–17.
32. Sánchez-Capelo A. Dual role for TGF-β1 in apoptosis. Cytokine Growth Factor Rev. 2005;16(1):15–34.
33. Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res. 2012;18(17):4514–21.
34. Padua D, Massagué J. Roles of TGFβ in metastasis. Cell Res. 2008;19(1):89–102.
35. Epstein FH, Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med. 2000;342(18):1350–8.
36. Semczuk A, Zakrzewski P, Forma E, Cygankiewicz A, Semczuk-Sikora A, Bryś M, et al. TGFβ-pathway is down-regulated in a uterine carcinosarcoma: a case study. Pathol Res Pract. 2013;209(11):740–4.
37. Beisner J, Buck MB, Fritz P, Dippon J, Schwab M, Brauch H, et al. A novel functional polymorphism in the transforming growth factor-β2 gene promoter and tumor progression in breast cancer. Cancer Res. 2006;66(15):7554–61.
38. Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, et al. miR-200a prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes. 2011;60:280–7.
39. Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, et al. The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 2012;302(3):F369–79.
40. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22(10):1686–98.
41. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68(19):7846–54.
42. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9(6):582–9.
43. Gregory PA. An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22:1686–98.